| Literature DB >> 19426478 |
Yuanyuan Wang1, Miranda L Davies-Tuck, Anita E Wluka, Andrew Forbes, Dallas R English, Graham G Giles, Richard O'Sullivan, Flavia M Cicuttini.
Abstract
INTRODUCTION: Fatty acids have been implicated in osteoarthritis (OA), yet the mechanism by which fatty acids affect knee structure and consequently the risk of knee OA has not been fully elucidated. Higher intakes of fatty acids have been shown to be associated with the risk of bone marrow lesions (BMLs) in a healthy population. The aim of this study was to examine the association between fatty acid consumption and the incidence of BMLs in healthy middle-aged adults without clinical knee OA.Entities:
Mesh:
Substances:
Year: 2009 PMID: 19426478 PMCID: PMC2714108 DOI: 10.1186/ar2688
Source DB: PubMed Journal: Arthritis Res Ther ISSN: 1478-6354 Impact factor: 5.156
Characteristics of study participants with no bone marrow lesions at baseline
| Incident BMLs | Without incident BMLs | ||
| Age, years | 57.6 (5.8) | 57.7 (5.0) | 0.91 |
| Number of females (percentage of females) | 23 (72%) | 120 (61%) | 0.22b |
| Body mass index, kg/m2 | 27.9 (5.3) | 25.4 (3.8) | 0.02 |
| Energy intake, kJ/d | 8,822 (3,019) | 9,293 (3,063) | 0.42 |
| Saturated fatty acid, g/day | 35.7 (1.2) | 33.0 (0.5) | 0.03c |
| Monounsaturated fatty acids, g/day | 29.3 (0.9) | 27.9 (0.4) | 0.14c |
| Polyunsaturated fatty acids, g/day | 12.7 (0.7) | 12.5 (0.3) | 0.76c |
| n-3 polyunsaturated fatty acids, g/day | 1.2 (0.05) | 1.2 (0.02) | 0.60c |
| n-6 polyunsaturated fatty acids, g/day | 11.3 (0.6) | 11.4 (0.3) | 0.92c |
| n-6/n-3 ratio | 9.6 (0.5) | 9.7 (0.2) | 0.82c |
Data are presented as mean (standard deviation) unless otherwise stated. aP value for comparisons between two groups using independent samples t test, bchi-square test, or cone-way analysis of covariance after adjusting for energy intake. BMLs, bone marrow lesions.
Relationship between fatty acid intake and incidence of bone marrow lesions
| Univariate analysis, OR (95% CI) | Model 1 | Model 2 | ||||
| Saturated fatty acids | 1.08 (0.72–1.60) | 0.73 | 2.62 (1.11–6.17) | 0.03 | 2.56 (1.03–6.37) | 0.04 |
| Monounsaturated fatty acids | 1.01 (0.66–1.52) | 0.98 | 2.10 (0.81–5.47) | 0.13 | 1.99 (0.75–5.31) | 0.17 |
| Polyunsaturated fatty acids | 0.94 (0.62–1.42) | 0.77 | 1.10 (0.64–1.90) | 0.74 | 1.10 (0.62–1.96) | 0.74 |
| n-6 polyunsaturated fatty acids | 0.88 (0.57–1.35) | 0.55 | 0.98 (0.56–1.70) | 0.93 | 0.98 (0.55–1.76) | 0.96 |
| n-3 polyunsaturated fatty acids | 0.81 (0.53–1.25) | 0.34 | 0.85 (0.46–1.56) | 0.60 | 0.85 (0.45–1.61) | 0.62 |
| n-6/n-3 ratio | 0.94 (0.63–1.38) | 0.74 | 0.96 (0.65–1.41) | 0.82 | 0.93 (0.61–1.42) | 0.74 |
aModel 1: odds ratio for development of tibiofemoral bone marrow lesions for each increase of 1 standard deviation in the respective fatty acid intake after adjusting for energy intake. bModel 2: odds ratio for development of tibiofemoral bone marrow lesions for each increase of 1 standard deviation in the respective fatty acid intake after adjusting for energy intake, age, gender, and body mass index. CI, confidence interval; OR, odds ratio.